PRLD
USDPrelude Therapeutics Incorporated Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$1.190
उच्च
$1.280
कम
$1.173
मात्रा
1.13M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
71.5M
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
1.27M
एक्सचेंज
NMS
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
संबंधित स्टॉक
MTAL
Metals Acquisition Limited Ordinary Shares
GSBD
Goldman Sachs BDC Inc.
HFWA
Heritage Financial Corporation
SENEB
Seneca Foods Corp.
FCNCO
First Citizens BancShares Inc. 5.625% Non-Cumulative Perpetual Preferred Stock Series C
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।